LABORATORIO ELEA PHOENIX S.A.

🇦🇷Argentina

Country: 🇦🇷Argentina

Ownership: -

Established: 2010-01-01

Employees: -

Market Cap: -

Website: http://ctbe.cnpem.br/

Clinical Trials

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

Phase 2

Recruiting

Conditions: Parkinson Disease

Interventions: Drug: Cannabidiol 100 mg/ml
Drug: cannabidiol 300 mg/ml
Drug: Placebo
Drug: Cannabidiol 400 mg/ml

First Posted Date: 2024-10-08

Last Posted Date: 2024-12-05

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 88

Registration Number: NCT06629389

Locations: 🇦🇷
Hospital Español de Mendoza, Mendoza, Argentina

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer Metastatic

Interventions: Drug: Pembrolizumab biosimilar
Drug: Pembrolizumab

First Posted Date: 2022-12-30

Last Posted Date: 2024-07-16

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 174

Registration Number: NCT05668650

Locations: 🇦🇷
Clínica Viedma, Viedma, Río Negro, Argentina

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease

Phase 3

Recruiting

Conditions: Chagas Disease

Interventions: Drug: Short regimen of benznidazole
Drug: Short treatment with benznidazole
Drug: Standard treatment with benznidazole

First Posted Date: 2021-05-21

Last Posted Date: 2023-11-30

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 300

Registration Number: NCT04897516

Locations: 🇦🇷
Fundación Huésped, Buenos Aires, Argentina
🇦🇷
Hospital Donación Francisco Santojanni, Buenos Aires, Argentina
🇦🇷
Centro de Chagas y Patología Regional, Hospital Independencia, Santiago Del Estero, Argentina

and more 3 locations

Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

Phase 3

Completed

Conditions: COVID-19 Virus Infection

Interventions: Biological: Inactivated SARS-CoV-2 vaccine (Vero cell)
Biological: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine

First Posted Date: 2020-09-23

Last Posted Date: 2022-01-12

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 3000

Registration Number: NCT04560881

Locations: 🇦🇷
Fundación Huésped, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷
Vacunar Liniers, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
🇦🇷
Vacunar Cañitas, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

and more 1 locations

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

Phase 2

Completed

Conditions: COVID-19 Drug Treatment

Interventions: Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.

First Posted Date: 2020-05-11

Last Posted Date: 2020-10-05

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 45

Registration Number: NCT04381884

Locations: 🇦🇷
Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina
🇦🇷
Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷
Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aires, Argentina

Telmisartan for Treatment of COVID-19 Patients

Phase 4

Completed

Conditions: COVID-19 Drug Treatment

Interventions: Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.

First Posted Date: 2020-04-21

Last Posted Date: 2020-12-24

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 400

Registration Number: NCT04355936

Locations: 🇦🇷
Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina
🇦🇷
Hospital Español de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Phase 3

Completed

Conditions: Age-Related Macular Degeneration

Interventions: Drug: Bevacizumab (Lumiere®)

First Posted Date: 2018-09-12

Last Posted Date: 2020-10-28

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 22

Registration Number: NCT03668054

Locations: 🇦🇷
Consultorios Médicos / Clínica de Cirugía Especializada S.A. (CCE), Buenos Aires, Argentina
🇦🇷
Consultorios Médicos Dr. Benisek, Buenos Aires, Argentina
🇦🇷
Instituto Scorsetti S.A., Buenos Aires, Argentina

Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Quetiapine

First Posted Date: 2017-10-23

Last Posted Date: 2017-10-23

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 24

Registration Number: NCT03317236

Locations: 🇦🇷
DominguezLab, Paraná, Entre Ríos, Argentina

Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Efavirenz, tenofovir disoproxil fumarate and emtricitabine

First Posted Date: 2017-10-13

Last Posted Date: 2017-10-13

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 24

Registration Number: NCT03309566

Locations: 🇦🇷
DominguezLab, Paraná, Entre Ríos, Argentina

Racotumomab in Patients With High-risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Drug: Racotumomab

First Posted Date: 2016-12-21

Last Posted Date: 2023-09-11

Lead Sponsor: Laboratorio Elea Phoenix S.A.

Target Recruit Count: 39

Registration Number: NCT02998983

Locations: 🇦🇷
Prof. Dr. J. P. Garrahan National Children's Hospital, Buenos Aires, Argentina
🇦🇷
Hospital Universitario Austral, Pilar, Buenos Aires, Argentina

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy